Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Change in Accured Expenses (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Change in Accured Expenses for 12 consecutive years, with $252000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 83.94% year-over-year to $252000.0, compared with a TTM value of -$9000.0 through Sep 2025, up 98.64%, and an annual FY2024 reading of -$995000.0, down 1230.68% over the prior year.
  • Change in Accured Expenses was $252000.0 for Q3 2025 at Lisata Therapeutics, down from $487000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.4 million in Q4 2023 and bottomed at -$1.8 million in Q1 2025.
  • Average Change in Accured Expenses over 3 years is -$179727.3, with a median of $137000.0 recorded in 2024.
  • The sharpest move saw Change in Accured Expenses crashed 81.66% in 2024, then skyrocketed 151.26% in 2025.
  • Year by year, Change in Accured Expenses stood at $1.4 million in 2023, then dropped by 23.83% to $1.1 million in 2024, then tumbled by 76.25% to $252000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for LSTA at $252000.0 in Q3 2025, $487000.0 in Q2 2025, and -$1.8 million in Q1 2025.